Novartis Hikes Sandoz Sales Guide As Separation Edges Closer
As Sandoz Biopharm Contact Manufacturing Unit Moved To Novartis IM Segment
Novartis reported 8% top-line growth for its Sandoz unit during the first quarter of 2023, one of the last before it is separated into a standalone company.
You may also be interested in...
Ahead of a Sandoz capital markets day on 8 June, Generics Bulletin explains what we know so far about the firm’s spinoff from parent company Novartis – as well as the questions that the companies are yet to answer.
Tracing its roots back to Basel in the late nineteenth century, Sandoz has confirmed the location of its new planned permanent headquarters post-spin.
Sandoz has received a formal European approval for its high-concentration Hyrimoz biosimilar rival to Humira, setting the stage for it to enter a market that also includes versions from Alvotech/Stada and Celltrion.